White Mulberry Leaves Extract Market Size & Share 2026-2035

White Mulberry Leaves Extract Market Size

The white mulberry leaves extract market was valued at USD 51.5 billion in 2025 and is projected to reach USD 167.6 billion by 2035, expanding at a CAGR of 12.5% over 2026 to 2035. According to the latest report published by Global Market Insights Inc., the market reaches USD 58 billion in 2026.

Demand is moving beyond traditional botanical supplementation because 1-deoxynojirimycin (DNJ) creates a measurable formulation rationale for glycemic-management products. The category also draws revenue from cosmetics, functional food, and pharmaceutical applications, reducing dependence on any single downstream purchasing cycle.

White mulberry leaf extract includes powder, liquid, capsule, and other delivery formats derived from *Morus alba* leaves. The commercial scope covers standardized and non-standardized extracts sold into dietary supplements, food and beverage, cosmetics and personal care, pharmaceuticals, and smaller specialty uses. It excludes finished consumer products whose value does not accrue to the extract ingredient itself. DNJ inhibits intestinal alpha-glucosidase activity, a mechanism relevant to post-meal carbohydrate absorption and the extract's blood-sugar-management positioning. ^{[1]World Health Organization (WHO), Diabetes, who.int}

Market value expanded from USD 35.6 billion in 2022 to USD 45.8 billion in 2024 at a 13.43% historic CAGR. The forecast trajectory adds USD 109.6 billion between 2026 and 2035. Growth moderates modestly from the historic pace as established supplement markets mature, but premium extract specifications and deeper channel access preserve double-digit expansion.

The sizing model triangulates producer and distributor revenue, downstream application demand, form-level mix, and regional purchasing patterns. Bottom-up estimates reconcile the value of powder, liquid, capsule, and other formats with application and channel demand. Top-down checks assess the addressable botanical-ingredient spend in nutraceutical, cosmetics, food, and pharmaceutical uses. Forecasts model mix effects rather than adding driver impacts mechanically.

The market's commercial center is shifting from raw botanical volume toward specification reliability. HPLC verification, cGMP production, organic qualification, and higher DNJ concentrations change the buying conversation from leaf sourcing to documentation, active-content consistency, and formulation efficiency. That shift supports premium pricing where pharmaceutical, clinical nutrition, and high-end cosmetics buyers require repeatable performance.

The category combines agricultural input exposure with technically demanding extraction and testing requirements. High-potency DNJ extracts have more commercial relevance than commodity powders because they reduce the mass of ingredient needed per finished dose. Multi-vertical demand also cushions the category: cosmetics buyers value tyrosinase-inhibiting flavonoids, while supplement and medical-food buyers focus on glucose-management formulations. ^{[2]Cosmetics & Toiletries, Tyrosinase Inhibition by Plant Extracts: A Dermatological Review, cosmeticsandtoiletries.com}

Key Drivers

Diabetes prevalence creates an addressable consumer need for products positioned around glucose management; the International Diabetes Federation projects 783 million adults with diabetes by 2045. ^{[3]International Diabetes Federation (IDF), IDF Diabetes Atlas, 10th Edition: Global Projections, diabetesatlas.org} DNJ's mechanism gives ingredient buyers a technical basis for product differentiation, although marketing claims remain subject to jurisdiction-specific rules. The operational consequence is greater demand for standardized active-content specifications and documented lot consistency. Suppliers that can link agronomy, extraction yield, and analytical release testing are better positioned to secure repeat procurement.

Preventive-health spending broadens demand beyond diagnosed patients. The global wellness economy was valued at more than USD 5.6 trillion, creating a favorable spending environment for nutritional and plant-derived ingredients. ^{[4]Global Wellness Institute, Global Wellness Economy Monitor, globalwellnessinstitute.org} That demand does not automatically translate into extract revenue; brands still need product formats, claims support, and channel access. The commercial implication is strongest for suppliers that can offer formulation support rather than only bulk material.

Advanced extraction alters both product economics and regulatory fit. Supercritical CO2 can reduce solvent-residue concerns, while enzymatic processing and HPLC testing improve reproducibility. The more consequential change is downstream: higher active-content density can reduce dosage mass, allowing use in capsules, sachets, beverages, and compact cosmetic formulations. This supports price realization when buyers value performance per gram rather than lowest delivered cost.

Key Restraints

Mulberry-leaf quality varies with maturity, harvest timing, and agronomic conditions, making raw-material consistency a recurring cost issue. Advanced extraction systems and HPLC quality-control programs add capital and recurring laboratory expense. The resulting market split is structural: suppliers able to fund verification can target premium customers, while smaller processors compete where specification requirements are lower. Qualification cycles can therefore become a barrier to entry rather than a routine compliance task.

Awareness limits demand conversion in markets where supplement retail and practitioner education remain less developed. Health expenditure and consumer purchasing power vary sharply across emerging economies, which constrains premium botanical uptake. E-commerce improves access but cannot substitute for credible product education. Distributors that pair digital reach with localized regulatory and clinical communication will have a stronger route to demand creation.

White Mulberry Leaves Extract Market Segment Analysis

By Form

Powder was the largest form segment, holding 45.3% of revenue and reaching USD 23.3 billion in 2025. Its leadership comes from transport stability, storage efficiency, and compatibility with tablet compression, capsule filling, beverage blends, and cosmetic formulation. Suppliers offer concentration-ratio products alongside DNJ-standardized grades, allowing brands to choose between cost-oriented and active-content-led procurement. Shaanxi Bolin Biotechnology, Shaanxi Hongda Phytochemistry, and Undersun Biomedtech participate in this format with graded extract portfolios.

Powder remains the base material for many finished-dose formats, making its volume position resilient even as liquid and capsule demand rises. The economic advantage is lower logistics complexity and broad manufacturing compatibility. Pharmaceutical and functional-food customers increasingly require HPLC release testing, which shifts value toward suppliers able to certify active content. Through 2035, powder will retain its central position, although premium value growth will increasingly depend on standardization rather than raw-volume expansion. ^{[5]ScienceDirect, Supercritical CO₂ Extraction of Phenolics from Morus alba, sciencedirect.com}

Liquid extracts held 35.2% of revenue, equivalent to USD 18.2 billion in 2025, and will grow at a 12.63% CAGR through 2035. Serums, toners, lotions, herbal teas, wellness shots, and ready-to-drink products create the core demand base. Cosmetics formulators use aqueous or glycerin-based liquids when they need incorporation into topical systems, while beverage developers value solubility and dose flexibility.

The segment requires pH control, preservative-system design, and microbiological management, creating a more demanding qualification path than dry powder. This technical burden supports premiums for liquids with defined polyphenol, flavonoid, or DNJ specifications. South Korean, Japanese, and Chinese skincare markets are important pull-through markets for cosmetic-grade liquids because brightening and antioxidant claims align with established product routines. Liquid formats will gain value share where formulators prioritize ease of incorporation and sensory performance.

Capsules accounted for 11.5% of market value, or USD 5.9 billion, in 2025 and will expand at an 11.89% CAGR through 2035. The format fits daily supplement routines and permits dose-controlled delivery of DNJ-standardized material. Jeeva Organic markets a 1% DNJ HPLC-verified extract, while Phytotech Extracts uses the Iminosol® brand to distinguish its *Morus alba* ingredient.

Capsule demand is supported by pharmacy and practitioner channels, where standardized dosage and professional recommendation matter. Yet younger consumers increasingly favor gummies, chewables, and food-based wellness formats. Capsule suppliers must therefore compete on clinical positioning, documentation, and convenience rather than treating encapsulation as sufficient differentiation. The format remains commercially relevant through 2035, but its growth rate trails more formulation-flexible forms.

Other forms, including soft gels, gummies, sachets, and powder sticks, held 8.0% of the market at USD 4.1 billion in 2025 and will expand at a 12.40% CAGR. These formats translate botanical efficacy into consumer-friendly delivery systems, particularly for wellness products that compete for repeat purchase. Flavor masking, active stability, and dose loading are the core formulation constraints.

The segment is innovation intensive because its formats require co-development across extract supplier, contract manufacturer, and brand owner. A successful gummy or stick-pack product can widen access among consumers who avoid capsules. The commercial implication is that suppliers with application laboratories and stability data will have an advantage over bulk-only vendors. Through 2028, format innovation will create more differentiation in finished products than in basic concentration ratios alone.

By Application

Dietary supplements represented 24.9% of market value, or USD 12.8 billion, in 2025, and will grow at a 12.45% CAGR through 2035. This segment converts DNJ's mechanism into blood-sugar-management, weight-wellness, and general-health positioning. The category benefits from direct-to-consumer marketing and repeat-use purchasing patterns, especially in North America and Europe.

Regulatory treatment matters because product claims must remain consistent with the applicable dietary-supplement framework. FDA guidance identifies dietary supplements as a distinct regulated category, shaping how brands position botanical ingredients. ^{[6]U.S. Food and Drug Administration (FDA), Dietary Supplements Overview, fda.gov} Suppliers gain commercial traction when they provide active-content documentation and ingredient identity support to brand customers. The segment will remain a key volume channel, but brands will increasingly demand substantiation that separates clinically credible products from generic wellness claims.

Food and beverage held 14.5% of revenue, or USD 7.5 billion, in 2025 and will expand at an 11.95% CAGR through 2035. Herbal teas, wellness shots, health bars, fortified cereals, and extract-infused drinks are the principal use cases. The functional beverage subsegment offers the most attractive route because it combines frequent consumption with visible health positioning.

Food formulation introduces constraints that supplements can avoid. Taste, color, shelf stability, and dose loading limit the use of higher-cost extracts. The Institute of Food Technologists identifies consumer interest in functional ingredients as a persistent product-development theme. Commercial success depends on delivery formats that meet sensory requirements without diluting the intended active-content story. Through 2030, high-concentration liquids and powder dispersions will be most relevant where beverage manufacturers need small-volume dosing.

Cosmetics and personal care was the largest application, holding 30.6% market share and reaching USD 15.8 billion in 2025. The segment will expand at a 12.83% CAGR through 2035. Rutin, quercetin, and related compounds support skin-brightening, antioxidant, and anti-inflammatory positioning, while tyrosinase inhibition aligns with hyperpigmentation and even-tone products.

The segment rewards formulation quality more than bulk volume. Liquid extracts with consistent color, odor, microbial control, and active-profile documentation are better suited to premium serums, creams, and masks. Cosmetic buyers also evaluate supplier traceability and sustainability claims because botanical provenance affects brand risk. Through 2028, cosmetic demand will continue to favor liquid and tailored specifications over undifferentiated extract powders.

Pharmaceuticals accounted for 20.5% of revenue, or USD 10.6 billion, in 2025 and will be the fastest-growing application at a 12.90% CAGR through 2035. The segment requires the most stringent standardization, stability testing, and documentation. DNJ's alpha-glucosidase activity creates a basis for investigation in metabolic-management and medical-food formulations.

This channel changes the supplier's operating model. Buyers require cGMP practices, validated analytical methods, and controlled specifications, not simply botanical availability. Primary research is unavailable in the approved evidence package; therefore, no interview, survey, or site-tracking claim is presented. The commercial implication remains clear: pharmaceutical-intent demand raises qualification costs but can support higher-value contracts through the 2027 to 2032 development window.

Other applications, including animal nutrition, agricultural uses, and emerging research categories, represented 9.5% of market value at USD 4.9 billion in 2025 and will grow at an 11.64% CAGR. These applications are smaller and less mature than the core consumer-health and cosmetics markets. Their upside depends on use-specific validation and commercial formulation development.

The segment provides optionality rather than a near-term volume engine. Suppliers can use smaller applications to diversify customer exposure, but should avoid allocating major capacity without defined customer demand. Through 2035, specialty uses may broaden the extract's market reach, although current value remains concentrated in established applications.

By Distribution Channel

Direct sales accounted for 24.5% of the market, or USD 12.6 billion, in 2025 and will grow at a 12.18% CAGR. The channel includes business-to-business ingredient supply to supplement, pharmaceutical, cosmetics, and food companies. It relies on specification co-development, quality audits, and long-term supply relationships.

Direct procurement is commercially important because it links qualified extract suppliers directly with brand and formulation customers. These relationships can support predictable volumes and reduce distributor margin layers. Yet they also intensify the supplier-audit burden, particularly for pharmaceutical-grade and certified-organic products. Direct sales will remain central for high-specification materials through 2035.

E-commerce and online platforms were the largest channel, holding 35.5% share and reaching USD 18.3 billion in 2025. The channel will grow at a 12.74% CAGR through 2035. Digital platforms connect health-focused consumers with branded supplements and enable business buyers to discover suppliers beyond established distributor networks. UNCTAD identifies e-commerce as a major channel for expanding digital market access.

Online distribution changes competitive economics by lowering entry barriers for brands while increasing the importance of search visibility, reviews, fulfillment, and compliance. Cross-border access is particularly relevant for China- and India-based suppliers seeking buyers in North America and Europe. The second-order effect is tighter pressure on offline exclusivity and greater need for brand-level differentiation. E-commerce will remain the category's largest channel, but platform concentration and claim compliance will shape margins.

Offline retail held 22.5% of revenue, or USD 11.6 billion, in 2025 and will be the fastest-growing defined channel at a 12.87% CAGR. Pharmacy, grocery, specialty health stores, and natural-product retailers remain important consumer access points. Physical retail offers product discovery and practitioner-adjacent credibility that online channels cannot fully reproduce.

Growth is strongest where health-product retail infrastructure develops before digital commerce reaches maturity. Retail placement also supports premium products that benefit from in-store education and professional recommendation. Suppliers entering this channel need packaging, regulatory labeling, and distributor support that differ from bulk ingredient sales. Through 2030, offline expansion in emerging markets will remain a material counterweight to the e-commerce narrative.

Other channels, including wholesalers, practitioner dispensing, and institutional procurement, represented 17.5% of market value at USD 9.0 billion in 2025 and will grow at a 12.04% CAGR. These routes serve buyers requiring clinical positioning, consolidated purchasing, or specialized distribution. Practitioner dispensing has relevance for pharmaceutical-grade and clinical-nutrition products.

The channel is smaller but strategically useful because professional recommendation can justify higher-value formulations. Procurement decisions prioritize documentation, continuity of supply, and dosage consistency. Its commercial contribution will remain tied to the growth of regulated and practitioner-influenced applications.

White Mulberry Leaves Extract Market Regional Analysis

Regional performance reflects a combination of cultivation and extraction capacity, regulatory thresholds, consumer-health spending, and channel maturity. Asia Pacific controls much of the raw-material and processing base, while Europe and North America reward documentation and high-specification products. Latin America and MEA have smaller current demand but represent future access opportunities as distribution and consumer education improve.

North America

North America reached USD 13.6 billion in 2025, including USD 11.6 billion from the United States, and will reach USD 43.2 billion by 2035 at a 12.21% CAGR. The region's supplement market, direct-to-consumer infrastructure, and established specialty retail support demand. FDA dietary-supplement oversight shapes product labeling and structure-function claim practices.

The United States is the primary regional demand center for supplement, functional-food, and cosmetic products. Canada provides a smaller but regulated natural-health-product market. A key constraint is that claims and ingredient documentation must withstand retailer, regulator, and consumer scrutiny. North American buyers will continue to favor suppliers with cGMP processes, active-content testing, and organic or other recognized certifications.

Europe

Europe was the fastest-growing region and will grow from USD 13.1 billion in 2025 to USD 43.9 billion by 2035 at a 12.83% CAGR. Germany, the United Kingdom, France, Spain, and Italy form the major demand centers. European Food Safety Authority review processes and the Novel Food framework raise the entry threshold for botanical ingredients while favoring qualified, traceable supply. ^{[7]European Food Safety Authority (EFSA), Novel Food Regulation and EU Botanical Ingredient Assessment, efsa.europa.eu}

Germany and France provide deep supplement and natural-product demand, while the UK remains a large consumer-health market. Italy and Spain add cosmetics and functional-food demand. The region's commercial constraint is the cost of evidence, safety, and documentation needed to pass supplier qualification. Through 2030, Europe will reward high-specification extracts more strongly than lower-priced commodity grades.

Asia Pacific

Asia Pacific was the largest region, reaching USD 15.8 billion in 2025 and projected to reach USD 53.3 billion by 2035 at a 12.90% CAGR. China anchors cultivation, extraction, and domestic demand, while India adds manufacturing diversification and expanding nutraceutical consumption. Japan, South Korea, and Australia contribute high-value cosmetics, functional-food, and supplement demand.

China's Shaanxi Province contains a concentration of suppliers including Shaanxi Bolin Biotechnology, Shaanxi Hongda Phytochemistry, Shaanxi SCIGROUND Biotechnology, and Xi'an Lanshan Biotechnology. The cluster reduces sourcing and processing costs but exposes global buyers to geographic concentration risk. India offers alternative sourcing through Phytotech Extracts, Jeeva Organic, and Nans Products. By 2028, supplier diversification will be a commercial requirement for buyers that need resilience as well as cost efficiency.

Latin America

Latin America reached USD 6.6 billion in 2025 and will grow to USD 20.8 billion by 2035 at a 12.20% CAGR. Brazil and Mexico are the principal markets, supported by population scale, pharmacy networks, and wider consumer-health spending. The region remains less penetrated than North America or Europe, which limits present value but creates room for expansion.

The primary barrier is awareness rather than botanical availability. Brands need localized education, compliant positioning, and reliable distribution to convert general wellness interest into repeat extract purchases. Offline retail and mobile-first commerce can develop in parallel rather than sequentially. Growth will improve through the latter forecast years if distributor networks support credible product education.

Middle East and Africa

The Middle East and Africa market reached USD 2.3 billion in 2025 and will reach USD 6.3 billion by 2035 at a 10.57% CAGR. Saudi Arabia and the UAE offer higher-value Gulf demand, while South Africa is the most developed sub-Saharan market. Diabetes burden and higher disposable income in selected Gulf markets support targeted wellness demand. ^{[8]World Health Organization (WHO), Global Health Observatory: Noncommunicable Diseases and Diabetes Burden by Region, who.int}

The regional constraint is uneven nutraceutical retail capacity and price sensitivity across many markets. Product availability alone will not create demand; importers and distributors need education-led commercialization and credible quality positioning. The region will remain smaller than other markets through 2035, but its premium urban centers offer selective opportunities for certified, high-potency products.

White Mulberry Leaves Extract Market Share & Competitive Landscape

Shaanxi Bolin Biotechnology led the market with a 9.8% share in 2025. The top five participants-Shaanxi Bolin Biotechnology, Shaanxi Hongda Phytochemistry, ETChem (Suzhou), Shaanxi SCIGROUND Biotechnology, and Naturalin Bio-Resources-held 38.5% collectively. The remaining 61.5% is distributed across regional and specialty suppliers, making the market fragmented rather than concentrated.

Shaanxi Bolin Biotechnology combines cultivation, extraction, purification, ingredient manufacturing, and global business-to-business distribution. Its August 2025 organic-certified extraction-facility commissioning expanded production capacity by 200%, strengthening its ability to serve pharmaceutical-grade and premium supplement demand. Shaanxi Hongda Phytochemistry competes through vertically integrated cultivation and product specifications spanning DNJ, flavonoid, and polyphenol needs.

ETChem (Suzhou) brings diversified natural-ingredient processing capability and global distribution infrastructure, although its specific white mulberry leaf extract SKU listing was not confirmed in the approved evidence package. Shaanxi SCIGROUND Biotechnology is a newer entity in the Xi'an cluster with commercial DNJ 1 to 5% and 10:1 products. Naturalin Bio-Resources introduced a 30% DNJ extract in November 2025, positioning it around active-content density and functional-food relevance.

Major players operating in the white mulberry leaves extract market include:

• Vertically integrated Chinese producers: Shaanxi Bolin Biotechnology, Shaanxi Hongda Phytochemistry, Shaanxi SCIGROUND Biotechnology, Tong Rui Bio-Tech, Xi'an Lanshan Biotechnology, and Undersun Biomedtech.

• Indian diversification and specialty suppliers: Phytotech Extracts, Jeeva Organic, and Nans Products.

• Regional phytochemical and ingredient participants: ETChem (Suzhou), Nutra Green Biotechnology, TOKIWA PHYTOCHEMICAL, and Naturalin Bio-Resources.

Phytotech Extracts differentiates with the Iminosol® branded ingredient, while Jeeva Organic emphasizes organic sourcing and HPLC-verified 1% DNJ. Nutra Green Biotechnology offers 10:1, 1-DNJ 1%, and flavones 5% grades. Tong Rui Bio-Tech and Undersun Biomedtech rely on integrated processing depth, and Nans Products adds India-origin mulberry-product experience. TOKIWA PHYTOCHEMICAL contributes long-standing Japanese phytochemical market presence.

Competition centers on qualification, not only price. DNJ concentration, HPLC verification, organic status, cGMP practice, and application support determine access to premium contracts. Mergers, partnerships, and capacity investments are likely to intensify from 2027 to 2030 as pharmaceutical-intent demand raises the cost of credible supply. The market remains open to challengers, but new entrants need analytical credibility and customer qualification before they can compete for higher-value business.

Recent Industry Developments

• Nov 2025: Naturalin Bio-Resources launched an ultra-concentrated white mulberry leaves extract standardized to 30% DNJ and associated the product with U.S. GRAS positioning. The development raises active-per-gram efficiency, making constrained-dose food and beverage formulations more feasible.
• Aug 2025: Shaanxi Bolin Biotechnology commissioned an organic-certified extraction facility and expanded production capacity by 200%. The investment increases available capacity for certified-organic, pharmaceutical-grade, and high-volume supplement demand, reinforcing the advantage of vertically integrated supply.